Evidence map›Paper›PMID 36648321›Full record

ArticleACS chemical biology2023

Acarbose May Function as a Competitive Exclusion Agent for the Producing Bacteria.

Samuel Tanoeyadi, Takeshi Tsunoda, Takuya Ito, Benjamin Philmus, Taifo Mahmud

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Enhancement of Acarbose Production inJournal of agricultural and food chemistry · 2025
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Samuel TanoeyadiDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507, United States.
Takeshi TsunodaDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507, United States.ORCID 0000-0002-4374-7863
Takuya ItoLaboratory of Natural Medicines, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 Nisikiorikita, Tondabayashi 584-8540, Japan.
Benjamin PhilmusDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507, United States.ORCID 0000-0003-2085-0873
Taifo MahmudDepartment of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331-3507, United States.ORCID 0000-0001-9639-526X
Oregon State University · USOsaka Ohtani University · JP

Funding

Biosynthetic studies and development of ribomimetic-based anti-infectivesR01AI129957 · NIAID · OREGON STATE UNIVERSITY · PI MAHMUD, TAIFO · 2018 to 2022
$1.8M
NIAID NIH HHS R01 AI129957
6 · The paper itself

Abstract

Acarbose is a well-known microbial specialized metabolite used clinically to treat type 2 diabetes. This natural pseudo-oligosaccharide (PsOS) shows potent inhibitory activity toward various glycosyl hydrolases, including α-glucosidases and α-amylases. While acarbose and other PsOSs are produced by many different bacteria, their ecological or biological role in microbial communities is still an open question. Here, we show that several PsOS-producing actinobacteria, i.e.,

Indexed as

ActinobacteriaDiabetes Mellitus, Type 2Acarbosealpha-AmylasesBacterial ProteinsHumansAcarbosealpha-AmylasesBacterial Proteins

Identifiers

PMID36648321
PMCPMC9957957
OpenAlexW4316928397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.